Analysis and management of avariation to a fluvial transport vessel caused by collision

In general, the body of the ship is a welded metal structure made up of the shell and bone. The paper aims is to analyze and present the solution for the collision damage to a river transport vessel. The problem is treated as in the case of a typical failure of welded constructions. In this regard, the fault will be described, after which the stages of the fault remedy will be presented

The failure of the floating cover of a vertical cylindrical tank

The location of oil tanks for the storage of volatile hydrocarbons could be done in geographical areas where the standard unit weight of the snow layer on the horizontal surface of the land reached 1500 ... 2000 N / m2 . The snow layer deposited on the floating cover under heavy weather conditions can cause a compressive force between 4500 and 6000 N / m2 . This creates problems in the operation of the tank and consequently the constructive structure of the floating cover can not bear this unitary load from the snow load, inevitably causing the damage. The capacities of the floating cover should be considered not only in terms of limitations on load-bearing considerations in general, but also in terms of the distribution of loads on the surface of the floating cover. The paper presents the aspect of the failure of a floating cover of a vertical cylindrical tank used to store liquid hydrocarbons under heavy climatic conditions

Considerations on damage to bulb turbine shafts from iron Gates II

During operation, the turbine bulb shaft is subjected to static specific stresses (tension, compression, torsion) and dynamic (fatigue, random vibrations). These stresses are the effect of hydraulic forces and moments developed on the rotor blade, the weight of the rotor (with or without oil) in the console and inevitable vibrations, which creates a rotating mass unevenly distributed over the axis of symmetry of the turbine. Observations made on the turbine bulb shafts of the Iron Gate II CHE have revealed cracks in the connection area of a shaft flange that engages it with the turbine rotor. Examination of these cracks leads to the conclusion that they are specific to the inevitable fatigue demands in exploiting the tree and enhancing the environment in which they work. Therefore, in the paper, a presentation and analysis of the damage of bulb turbine shafts from CHE Porţile de Fier II, after a significant number of hours of operation

Draft genome sequence of antarctic psychrotroph Streptomyces fildesensis strain INACH3013, isolated from King George Island soil

The draft genome sequence of Streptomyces fildesensis strain INACH3013, a psychrotrophic bacterium isolated from Northwest Antarctic soil, was reported. The genome sequence totaling 9,306,785 bp resulted from 122 contigs characterized by a GC content of 70.55%

Alpha-lipoic acid for diabetic peripheral neuropathy.

Diabetic peripheral neuropathy (DPN) is a frequent complication in people living with type 1 or type 2 diabetes. There is currently no effective treatment for DPN. Although alpha-lipoic acid (ALA, also known as thioctic acid) is widely used, there is no consensus about its benefits and harms. To assess the effects of alpha-lipoic acid as a disease-modifying agent in people with diabetic peripheral neuropathy. On 11 September 2022, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and two clinical trials registers. We also searched the reference lists of the included studies and relevant review articles for additional references not identified by the electronic searches. We included randomised clinical trials (RCTs) that compared ALA with placebo in adults (aged 18 years or older) and that applied the study interventions for at least six months. There were no language restrictions. We used standard methods expected by Cochrane. The primary outcome was change in neuropathy symptoms expressed as changes in the Total Symptom Score (TSS) at six months after randomisation. Secondary outcomes were change in neuropathy symptoms at six to 12 months and at 12 to 24 months, change in impairment, change in any validated quality of life total score, complications of DPN, and adverse events. We assessed the certainty of the evidence using GRADE. Our analysis incorporated three trials involving 816 participants. Two studies included people with type 1 or type 2 diabetes, while one study included only people with type 2 diabetes. The duration of treatment was between six months and 48 months. We judged all studies at high risk of overall bias due to attrition. ALA compared with placebo probably has little or no effect on neuropathy symptoms measured by TSS (lower score is better) after six months (mean difference (MD) -0.16 points, 95% confidence interval (CI) -0.83 to 0.51; 1 study, 330 participants; moderate-certainty evidence). The CI of this effect estimate did not contain the minimal clinically important difference (MCID) of 0.97 points. ALA compared with placebo may have little or no effect on impairment measured by the Neuropathy Impairment Score-Lower Limbs (NIS-LL; lower score is better) after six months (MD -1.02 points, 95% CI -2.93 to 0.89; 1 study, 245 participants; low-certainty evidence). However, we cannot rule out a significant benefit, because the lower limit of the CI surpassed the MCID of 2 points. There is probably little or no difference between ALA and placebo in terms of adverse events leading to cessation of treatment within six months (risk ratio (RR) 1.48, 95% CI 0.50 to 4.35; 3 studies, 1090 participants; moderate-certainty evidence). No studies reported quality of life or complications associated with DPN. Our analysis suggests that ALA probably has little or no effect on neuropathy symptoms or adverse events at six months, and may have little or no effect on impairment at six months. All the studies were at high risk of attrition bias. Therefore, future RCTs should ensure complete follow-up and transparent reporting of any participants missing from the analyses